Mechanisms of disease: Role of neurotrophins in diabetes and diabetic neuropathy

Handbook of Clinical Neurology

Volumn 126, Issue , 2014, Pages 443-460

  Verge, Valerie M K ^a   Andreassen, Christer S ^c   Arnason, Terra G ^a,b   Andersen, Henning ^c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

BDNF; Clinical trial; Diabetes; Diabetic neuropathy; Hyperglycemia; Neurotrophins; NGF; NT 3; P75NTR; TrkB

Indexed keywords

NERVE GROWTH FACTOR;

ANIMAL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHIES; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIABETIC NEUROPATHIES; HUMANS; NERVE GROWTH FACTORS;

EID: 84921962798     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53480-4.00032-1     Document Type: Chapter

References (203)

1. Aid T., Kazantseva A., Piirsoo M., et al. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res 2007, 85:525-535.
2. Al-Gayyar M.M., Matragoon S., Pillai B.A., et al. Epicatechin blocks pro-nerve growth factor (proNGF)-mediated retinal neurodegeneration via inhibition of p75 neurotrophin receptor expression in a rat model of diabetes [corrected]. Diabetologia 2011, 54:669-680.
3. Ali T.K., Matragoon S., Pillai B.A., et al. Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes. Diabetes 2008, 57:889-898.
4. Ali T.K., Al-Gayyar M.M., Matragoon S., et al. Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia 2011, 54:657-668.
5. Aloe L., Tirassa P., Lambiase A. The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers. Pharmacol Res 2008, 57:253-258.
6. American Association of Diabetes Educators Intensive diabetes management: implications of the DCCT and UKPDS. Diabetes Educ 2002, 28:735-740.
7. Anand P., Terenghi G., Warner G., et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 1996, 2:703-707.
8. Andreassen C.S., Jakobsen J., Andersen H. Muscle weakness: a progressive late complication in diabetic distal symmetric polyneuropathy. Diabetes 2006, 55:806-812.
9. Andreassen C.S., Jakobsen J., Flyvbjerg A., et al. Expression of neurotrophic factors in diabetic muscle - relation to neuropathy and muscle strength. Brain 2009, 132:2724-2733.
10. Apfel S.C. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?. Int Rev Neurobiol 2002, 50:393-413.
11. Apfel S.C., Kessler J.A., Adornato B.T., et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998, 51:695-702.
12. Apfel S.C., Schwartz S., Adornato B.T., et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000, 284:2215-2221.
13. Araya A.V., Orellana X., Espinoza J. Evaluation of the effect of caloric restriction on serum BDNF in overweight and obese subjects: preliminary evidences. Endocrine 2008, 33:300-304.
14. Barakat A., Skoglund G., Boissard C., et al. Calcitonin gene-related peptide and islet amyloid polypeptide stimulate insulin secretion in RINm5F cells through a common receptor coupled to a generation of cAMP. Biosci Rep 1994, 14:1-13.
15. Bariohay B., Lebrun B., Moyse E., et al. Brain-derived neurotrophic factor plays a role as an anorexigenic factor in the dorsal vagal complex. Endocrinology 2005, 146:5612-5620.
16. Bartness T.J., Shrestha Y.B., Vaughan C.H., et al. Sensory and sympathetic nervous system control of white adipose tissue lipolysis. Mol Cell Endocrinol 2010, 318:34-43.
17. Beattie M.S., Harrington A.W., Lee R., et al. ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron 2002, 36:375-386.
18. Beiswenger K.K., Calcutt N.A., Mizisin A.P. Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem 2008, 110:351-362.
19. Bhattacharyya O.K., Estey E.A., Cheng A.Y. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician 2009, 55:39-43.
20. Bibel M., Hoppe E., Barde Y.A. Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. EMBO J 1999, 18:616-622.
21. Boado R.J., Zhang Y., Zhang Y., et al. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng 2007, 97:1376-1386.
22. Boulton A.J. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev 2008, 24(Suppl 1):S3-S6.
23. Bramham C.R. Control of synaptic consolidation in the dentate gyrus: mechanisms, functions, and therapeutic implications. Prog Brain Res 2007, 163:453-471.
24. Brewster W.J., Fernyhough P., Diemel L.T., et al. Diabetic neuropathy, nerve growth factor and other neurotrophic factors. Trends Neurosci 1994, 17:321-325.
25. Bullo M., Peeraully M.R., Trayhurn P., et al. Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. Eur J Endocrinol 2007, 157:303-310.
26. Calcutt N.A., Jolivalt C.G., Fernyhough P. Growth factors as therapeutics for diabetic neuropathy. Curr Drug Targets 2008, 9:47-59.
27. Calcutt N.A., Cooper M.E., Kern T.S., et al. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 2009, 8:417-429.
28. Cao L., Lin E.J., Cahill M.C., et al. Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nat Med 2009, 15:447-454.
29. Caporali A., Pani E., Horrevoets A.J., et al. Neurotrophin p75 receptor (p75NTR) promotes endothelial cell apoptosis and inhibits angiogenesis: implications for diabetes-induced impaired neovascularization in ischemic limb muscles. Circ Res 2008, 103:e15-e26.
30. Casaccia-Bonnefil P., Carter B.D., Dobrowsky R.T., et al. Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature 1996, 383:716-719.
31. Chaldakov GN, Tonchev AB, Manni L et al. (2007). Comment on: Krabbe KS, Nielsen AR, Krogh-Madsen R et al (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. (Diabetologia 50: 431-438.) Diabetologia 50: 1781-1782.
32. Chattopadhyay M., Mata M., Goss J., et al. Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer. Diabetologia 2007, 50:1550-1558.
33. Chaudhry V., Giuliani M., Petty B.G., et al. Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects. Muscle Nerve 2000, 23:189-192.
34. Cheng H.T., Dauch J.R., Hayes J.M., et al. Nerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes. J Neuropathol Exp Neurol 2009, 68:1229-1243.
35. Chilton L., Middlemas A., Gardiner N., et al. The p75 neurotrophin receptor appears in plasma in diabetic rats-characterisation of a potential early test for neuropathy. Diabetologia 2004, 47:1924-1930.
36. Chuang H.H., Prescott E.D., Kong H., et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001, 411:957-962.
37. Clewes O., Fahey M.S., Tyler S.J., et al. Human ProNGF: biological effects and binding profiles at TrkA, P75NTR and sortilin. J Neurochem 2008, 107:1124-1135.
38. Comelli F., Bettoni I., Colombo A., et al. Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice. Eur J Pharmacol 2010, 637:62-69.
39. Cone R.D. Studies on the physiological functions of the melanocortin system. Endocr Rev 2006, 27:736-749.
40. Das U.N. Obesity: genes, brain, gut, and environment. Nutrition 2010, 26:459-473.
41. Deppmann C.D., Mihalas S., Sharma N., et al. A model for neuronal competition during development. Science 2008, 320:369-373.
42. Diemel L.T., Cai F., Anand P., et al. Increased nerve growth factor mRNA in lateral calf skin biopsies from diabetic patients. Diabet Med 1999, 16:113-118.
43. DiStefano P.S., Johnson E.M. Identification of a truncated form of the nerve growth factor receptor. Proc Natl Acad Sci U S A 1988, 85:270-274.
44. Dobrowsky R.T., Rouen S., Yu C. Altered neurotrophism in diabetic neuropathy: spelunking the caves of peripheral nerve. J Pharmacol Exp Ther 2005, 313:485-491.
45. Dodt C., Lonnroth P., Wellhoner J.P., et al. Sympathetic control of white adipose tissue in lean and obese humans. Acta Physiol Scand 2003, 177:351-357.
46. Domeniconi M., Chao M.V. Transactivation of Trk receptors in spinal motor neurons. Histol Histopathol 2010, 25:1207-1213.
47. Duan W., Guo Z., Jiang H., et al. Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 2003, 144:2446-2453.
48. Dyck P.J., Bushek W., Spring E.M., et al. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care 1987, 10:432-440.
49. Dyck P.J., Davies J.L., Litchy W.J., et al. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997, 49:229-239.
50. Faradji V., Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 1990, 81:402-406.
51. Fasanella K.E., Christianson J.A., Chanthaphavong R.S., et al. Distribution and neurochemical identification of pancreatic afferents in the mouse. J Comp Neurol 2008, 509:42-52.
52. Fernyhough P., Calcutt N.A. Abnormal calcium homeostasis in peripheral neuropathies. Cell Calcium 2010, 47:130-139.
53. Fernyhough P., Diemel L.T., Brewster W.J., et al. Altered neurotrophin mRNA levels in peripheral nerve and skeletal muscle of experimentally diabetic rats. J Neurochem 1995, 64:1231-1237.
54. Fliers E., Kreier F., Voshol P.J., et al. White adipose tissue: getting nervous. J Neuroendocrinol 2003, 15:1005-1010.
55. Friedman W.J. Neurotrophins induce death of hippocampal neurons via the p75 receptor. J Neurosci 2000, 20:6340-6346.
56. Fujimura H., Altar C.A., Chen R., et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002, 87:728-734.
57. Galkowska H., Olszewski W.L., Wojewodzka U., et al. Neurogenic factors in the impaired healing of diabetic foot ulcers. J Surg Res 2006, 134:252-258.
58. Garcia N., Santafe M.M., Tomas M., et al. Neurotrophin-4 couples to locally modulated ACh release at the end of neuromuscular synapse maturation. Neurosci Lett 2010, 468:72-74.
59. Garcia N., Tomas M., Santafe M.M., et al. Localization of brain-derived neurotrophic factor, neurotrophin-4, tropomyosin-related kinase b receptor, and p75 NTR receptor by high-resolution immunohistochemistry on the adult mouse neuromuscular junction. J Peripher Nerv Syst 2010, 15:40-49.
60. Generini S., Tuveri M.A., Matucci Cerinic M., et al. Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. Exp Clin Endocrinol Diabetes 2004, 112:542-544.
61. Genuth S. The UKPDS and its global impact. Diabet Med 2008, 25(Suppl 2):57-62.
62. Giordano A., Morroni M., Santone G., et al. Tyrosine hydroxylase, neuropeptide Y, substance P, calcitonin gene-related peptide and vasoactive intestinal peptide in nerves of rat periovarian adipose tissue: an immunohistochemical and ultrastructural investigation. J Neurocytol 1996, 25:125-136.
63. Goss J.R., Goins W.F., Lacomis D., et al. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes 2002, 51:2227-2232.
64. Graiani G., Emanueli C., Desortes E., et al. Nerve growth factor promotes reparative angiogenesis and inhibits endothelial apoptosis in cutaneous wounds of type 1 diabetic mice. Diabetologia 2004, 47:1047-1054.
65. Gram D.X., Ahrén B., Nagy I., et al. Capsaicin-sensitive sensory fibers in the islets of Langerhans contribute to defective insulin secretion in Zucker diabetic rat, an animal model for some aspects of human type 2 diabetes. Eur J Neurosci 2007, 25:213-223.
66. Gratto K.A., Verge V.M. Neurotrophin-3 down-regulates trkA mRNA, NGF high-affinity binding sites, and associated phenotype in adult DRG neurons. Eur J Neurosci 2003, 18:1535-1548.
67. Gray J., Yeo G.S., Cox J.J., et al. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 2006, 55:3366-3371.
68. Greenberg M.E., Xu B., Lu B., et al. New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci 2009, 29:12764-12767.
69. Han J.C., Muehlbauer M.J., Cui H.N., et al. Lower brain-derived neurotrophic factor in patients with Prader-Willi syndrome compared to obese and lean control subjects. J Clin Endocrinol Metab 2010, 95:3532-3536.
70. Harrington A.W., Leiner B., Blechschmitt C., et al. Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl Acad Sci U S A 2004, 101:6226-6230.
71. Hellweg R., Raivich G., Hartung H.D., et al. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol 1994, 130:24-30.
72. Hempstead B.L., Martin-Zanca D., Kaplan D.R., et al. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature 1991, 350:678-683.
73. Hermansen K., Ahren B. Dual effects of calcitonin gene-related peptide on insulin secretion in the perfused dog pancreas. Regul Pept 1990, 27:149-157.
74. Hollis G., Huber R. 11beta-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes Obes Metab 2011, 13:1-6.
75. Horton A., Laramee G., Wyatt S., et al. NGF binding to p75 enhances the sensitivity of sensory and sympathetic neurons to NGF at different stages of development. Mol Cell Neurosci 1997, 10:162-172.
76. Hruska R.E., Chertack M.M., Kravis D. Elevation of nerve growth factor receptor-truncated in the urine of patients with diabetic neuropathy. Ann N Y Acad Sci 1993, 679:349-351.
77. Huang T.J., Sayers N.M., Fernyhough P., et al. Diabetes-induced alterations in calcium homeostasis in sensory neurones of streptozotocin-diabetic rats are restricted to lumbar ganglia and are prevented by neurotrophin-3. Diabetologia 2002, 45:560-570. pmid:12032634.
78. Huang T.J., Sayers N.M., Verkhratsky A., et al. Neurotrophin-3 prevents mitochondrial dysfunction in sensory neurons of streptozotocin-diabetic rats. Exp Neurol 2005, 194:279-283.
79. Huang Y.Z., Pan E., Xiong Z.Q., et al. Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron 2008, 57:546-558.
80. Humpert P.M., Kopf S., Djuric Z., et al. Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients. Diabetologia 2007, 50:1517-1522.
81. Hwang J.J., Park M.H., Koh J.Y. Copper activates TrkB in cortical neurons in a metalloproteinase-dependent manner. J Neurosci Res 2007, 85:2160-2166.
82. Ieda M., Kanazawa H., Ieda Y., et al. Nerve growth factor is critical for cardiac sensory innervation and rescues neuropathy in diabetic hearts. Circulation 2006, 114:2351-2363.
83. Jang S.W., Liu X., Yepes M., et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci U S A 2010, 107:2687-2692.
84. Jansen P., Giehl K., Nyengaard J.R., et al. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat Neurosci 2007, 10:1449-1457.
85. Kakinoki B., Sekimoto S., Yuki S., et al. Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals. Diabetes 2006, 55:616-621.
86. Karchewski L.A., Gratto K.A., Wetmore C., et al. Dynamic patterns of BDNF expression in injured sensory neurons: differential modulation by NGF and NT-3. Eur J Neurosci 2002, 16:1449-1462.
87. Kenchappa R.S., Zampieri N., Chao M.V., et al. Ligand-dependent cleavage of the P75 neurotrophin receptor is necessary for NRIF nuclear translocation and apoptosis in sympathetic neurons. Neuron 2006, 50:219-232.
88. Kenchappa R.S., Tep C., Korade Z., et al. p75 neurotrophin receptor-mediated apoptosis in sympathetic neurons involves a biphasic activation of JNK and up-regulation of tumor necrosis factor-alpha-converting enzyme/ADAM17. J Biol Chem 2010, 285:20358-20368.
89. Kennedy A.J., Wellmer A., Facer P., et al. Neurotrophin-3 is increased in skin in human diabetic neuropathy. J Neurol Neurosurg Psychiatry 1998, 65:393-395.
90. Kernie S.G., Liebl D.J., Parada L.F. BDNF regulates eating behavior and locomotor activity in mice. EMBO J 2000, 19:1290-1300.
91. Kichev A., Ilieva E.V., Pinol-Ripoll G., et al. Cell death and learning impairment in mice caused by in vitro modified pro-NGF can be related to its increased oxidative modifications in Alzheimer disease. Am J Pathol 2009, 175:2574-2585.
92. Kim H.C., Cho Y.J., Ahn C.W., et al. Nerve growth factor and expression of its receptors in patients with diabetic neuropathy. Diabet Med 2009, 26:1228-1234.
93. Kolbeck R., Jungbluth S., Barde Y.A. Characterisation of neurotrophin dimers and monomers. Eur J Biochem 1994, 225:995-1003.
94. Kosacka J., Nowicki M., Kacza J., et al. Adipocyte-derived angiopoietin-1 supports neurite outgrowth and synaptogenesis of sensory neurons. J Neurosci Res 2006, 83:1160-1169.
95. Krabbe K.S., Nielsen A.R., Krogh-Madsen R., et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007, 50:431-438.
96. Kust B.M., Copray J.C., Brouwer N., et al. Elevated levels of neurotrophins in human biceps brachii tissue of amyotrophic lateral sclerosis. Exp Neurol 2002, 177:419-427.
97. Larrieta M.E., Vital P., Mendoza-Rodríguez A., et al. Nerve growth factor increases in pancreatic beta cells after streptozotocin-induced damage in rats. Exp Biol Med (Maywood) 2006, 231:396-402.
98. Lee P.G., Hohman T.C., Cai F., et al. Streptozotocin-induced diabetes causes metabolic changes and alterations in neurotrophin content and retrograde transport in the cervical vagus nerve. Exp Neurol 2001, 170:149-161.
99. Leinninger G.M., Vincent A.M., Feldman E.L. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst 2004, 9:26-53.
100. Levi-Montalcini R., Angeletti P.U. Essential role of the nerve growth factor in the survival and maintenance of dissociated sensory and sympathetic embryonic nerve cells in vitro. Dev Biol 1963, 7:653-659.
101. Lewin G.R., Barde Y.A. Physiology of the neurotrophins. Annu Rev Neurosci 1996, 19:289-317.
102. Lewin G.R., Mendell L.M. Nerve growth factor and nociception. Trends Neurosci 1993, 16:353-359.
103. Lindberger M., Schroder H.D., Schultzberg M., et al. Nerve fibre studies in skin biopsies in peripheral neuropathies. I. Immunohistochemical analysis of neuropeptides in diabetes mellitus. J Neurol Sci 1989, 93:289-296.
104. Loos R.J., Lindgren C.M., Li S., et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008, 40:768-775.
105. Lu B., Pang P.T., Woo N.H. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005, 6:603-614.
106. Marconi A., Terracina M., Fila C., et al. Expression and function of neurotrophins and their receptors in cultured human keratinocytes. J Invest Dermatol 2003, 121:1515-1521.
107. Martínez-Tellez R., Gomez-Villalobos Mde J., Flores G. Alteration in dendritic morphology of cortical neurons in rats with diabetes mellitus induced by streptozotocin. Brain Res 2005, 1048:108-115.
108. Masoudi R., Ioannou M.S., Coughlin M.D., et al. Biological activity of nerve growth factor precursor is dependent upon relative levels of its receptors. J Biol Chem 2009, 284:18424-18433.
109. Messier C. Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. Neurobiol Aging 2005, 26(Suppl 1):26-30.
110. Mischel P.S., Smith S.G., Vining E.R., et al. The extracellular domain of p75NTR is necessary to inhibit neurotrophin-3 signaling through TrkA. J Biol Chem 2001, 276:11294-11301.
111. Mizisin A.P., Bache M., DiStefano P.S., et al. BDNF attenuates functional and structural disorders in nerves of galactose-fed rats. J Neuropathol Exp Neurol 1997, 56:1290-1301.
112. Ng M.C., Tam C.H., So W.Y., et al. Implication of genetic variants near NEGR1, SEC16B, TMEM18, ETV5/DGKG, GNPDA2, LIN7C/BDNF, MTCH2, BCDIN3D/FAIM2, SH2B1, FTO, MC4R, and KCTD15 with obesity and type 2 diabetes in 7705 Chinese. J Clin Endocrinol Metab 2010, 95:2418-2425.
113. Nitta A., Murai R., Suzuki N., et al. Diabetic neuropathies in brain are induced by deficiency of BDNF. Neurotoxicol Teratol 2002, 24:695-701.
114. Nolano M., Provitera V., Caporaso G., et al. Quantification of pilomotor nerves: a new tool to evaluate autonomic involvement in diabetes. Neurology 2010, 75:1089-1097.
115. Ono M., Itakura Y., Nonomura T., et al. Intermittent administration of brain-derived neurotrophic factor ameliorates glucose metabolism in obese diabetic mice. Metabolism 2000, 49:129-133.
116. Pan W., Banks W.A., Fasold M.B., et al. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37:1553-1561.
117. Park K.S., Kim S.S., Kim J.C., et al. Serum and tear levels of nerve growth factor in diabetic retinopathy patients. Am J Ophthalmol 2008, 145:432-437.
118. Parkhurst C.N., Zampieri N., Chao M.V. Nuclear localization of the p75 neurotrophin receptor intracellular domain. J Biol Chem 2010, 285:5361-5368.
119. Pedersen B.K., Pedersen M., Krabbe K.S., et al. Role of exercise-induced brain-derived neurotrophic factor production in the regulation of energy homeostasis in mammals. Exp Physiol 2009, 94:1153-1160.
120. Pedraza C.E., Podlesniy P., Vidal N., et al. Pro-NGF isolated from the human brain affected by Alzheimer's disease induces neuronal apoptosis mediated by p75NTR. Am J Pathol 2005, 166:533-543.
121. Peeraully M.R., Jenkins J.R., Trayhurn P. NGF gene expression and secretion in white adipose tissue: regulation in 3T3-L1 adipocytes by hormones and inflammatory cytokines. Am J Physiol Endocrinol Metab 2004, 287:E331-E339.
122. Phillips R.J., Powley T.L. Gastric volume rather than nutrient content inhibits food intake. Am J Physiol 1996, 271:R766-R769.
123. Pierucci D., Cicconi S., Bonini P., et al. NGF-withdrawal induces apoptosis in pancreatic beta cells in vitro. Diabetologia 2001, 44:1281-1295.
124. Pittenger G., Vinik A. Nerve growth factor and diabetic neuropathy. Exp Diabesity Res 2003, 4:271-285.
125. Post J.I., Eibl J.K., Ross G.M. Zinc induces motor neuron death via a selective inhibition of brain-derived neurotrophic factor activity. Amyotroph Lateral Scler 2008, 9:149-155.
126. Pruunsild P., Kazantseva A., Aid T., et al. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007, 90:397-406.
127. Pu L.L., Syed S.A., Reid M., et al. Effects of nerve growth factor on nerve regeneration through a vein graft across a gap. Plast Reconstr Surg 1999, 104:1379-1385.
128. Rasmussen P., Brassard P., Adser H., et al. Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp Physiol 2009, 94:1062-1069.
129. Razavi R., Chan Y., Afifiyan F.N., et al. TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell 2006, 127:1123-1135.
130. Reichardt L.F. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006, 361:1545-1564.
131. Renn C.L., Leitch C.C., Dorsey S.G. In vivo evidence that truncated trkB.T1 participates in nociception. Mol Pain 2009, 5:61.
132. Roberson M.D., Toews A.D., Bouldin T.W., et al. NGFR-mRNA expression in sciatic nerve: a sensitive indicator of early stages of axonopathy. Brain Res Mol Brain Res 1995, 28:231-238.
133. Rodriguez-Pena A., Botana M., Gonzalez M., et al. Expression of neurotrophins and their receptors in sciatic nerve of experimentally diabetic rats. Neurosci Lett 1995, 200:37-40.
134. Rosenbaum T., Castanares D.T., Lopez-Valdes H.E., et al. Nerve growth factor increases L-type calcium current in pancreatic beta cells in culture. J Membr Biol 2002, 186:177-184.
135. Ross G.M., Shamovsky I.L., Lawrance G., et al. Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins. Nat Med 1997, 3:872-878.
136. Ross G.M., Shamovsky I.L., Woo S.B., et al. The binding of zinc and copper ions to nerve growth factor is differentially affected by pH: implications for cerebral acidosis. J Neurochem 2001, 78:515-523.
137. Sahenk Z., Galloway G., Edwards C., et al. TrkB and TrkC agonist antibodies improve function, electrophysiologic and pathologic features in Trembler J mice. Exp Neurol 2010, 224:495-506.
138. Sakuma K., Watanabe K., Sano M., et al. A possible role for BDNF, NT-4 and TrkB in the spinal cord and muscle of rat subjected to mechanical overload, bupivacaine injection and axotomy. Brain Res 2001, 907:1-19.
139. Salis M.B., Graiani G., Desortes E., et al. Nerve growth factor supplementation reverses the impairment, induced by type 1 diabetes, of hindlimb post-ischaemic recovery in mice. Diabetologia 2004, 47:1055-1063.
140. Scarpini E., Beretta S., Ross A.H., et al. Rapid quantitative immunohistochemical assessment of human peripheral neuropathies using a monoclonal antibody against nerve growth factor receptor. J Neurol 1989, 236:439-444.
141. Scarpini E., Conti G., Chianese L., et al. Induction of p75NGFR in human diabetic neuropathy. J Neurol Sci 1996, 135:55-62.
142. Schecterson L.C., Hudson M.P., Ko M., et al. Trk activation in the secretory pathway promotes Golgi fragmentation. Mol Cell Neurosci 2010, 43:403-413.
143. Schmid H., Forman L.A., Cao X., et al. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes. Diabetes 1999, 48:603-608.
144. Selim M.M., Wendelschafer-Crabb G., Redmon J.B., et al. Gastric mucosal nerve density: a biomarker for diabetic autonomic neuropathy?. Neurology 2010, 75:973-981.
145. Sheard PW, Bewick GS, Woolley AG et al. (2010). Investigation of neuromuscular abnormalities in neurotrophin-3-deficient mice. Eur J Neurosci 31: 29-41. Epub 2009 Dec 18 PMID: 20092553. http://dx.doi.org/10.1111/j.1460-9568.2009.07032.x.
146. Shi H., Bartness T.J. White adipose tissue sensory nerve denervation mimics lipectomy-induced compensatory increases in adiposity. Am J Physiol Regul Integr Comp Physiol 2005, 289:R514-R520.
147. Shi H., Song C.K., Giordano A., et al. Sensory or sympathetic white adipose tissue denervation differentially affects depot growth and cellularity. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1028-R1037.
148. Shu X., Mendell L.M. Acute sensitization by NGF of the response of small-diameter sensory neurons to capsaicin. J Neurophysiol 2001, 86:2931-2938.
149. Silhol M., Bonnichon V., Rage F., et al. Age-related changes in brain-derived neurotrophic factor and tyrosine kinase receptor isoforms in the hippocampus and hypothalamus in male rats. Neuroscience 2005, 132:613-624.
150. Snider W.D. Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell 1994, 77:627-638.
151. Sobue G., Yasuda T., Mitsuma T., et al. Expression of nerve growth factor receptor in human peripheral neuropathies. Ann Neurol 1988, 24:64-72.
152. Sornelli F., Fiore M., Chaldakov G.N., et al. Adipose tissue-derived nerve growth factor and brain-derived neurotrophic factor: results from experimental stress and diabetes. Gen Physiol Biophys 2009, 28:179-183.
153. Stranahan A.M., Mattson M.P. Bidirectional metabolic regulation of neurocognitive function. Neurobiol Learn Mem 2011, 96:507-516.
154. Stranahan A.M., Lee K., Martin B., et al. Voluntary exercise and caloric restriction enhance hippocampal dendritic spine density and BDNF levels in diabetic mice. Hippocampus 2009, 19:951-961.
155. Stranahan A.M., Zhou Y., Martin B., et al. Pharmacomimetics of exercise: novel approaches for hippocampally-targeted neuroprotective agents. Curr Med Chem 2009, 16:4668-4678.
156. Suter U., Heymach J.V., Shooter E.M. Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF. EMBO J 1991, 10:2395-2400.
157. Suwa M., Kishimoto H., Nofuji Y., et al. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metabolism 2006, 55:852-857.
158. Suwa M., Yamamoto K.I., Nakano H., et al. Brain-derived neurotrophic factor treatment increases the skeletal muscle glucose transporter 4 protein expression in mice. Physiol Res 2010, 59:619-623.
159. Taniuchi M., Clark H.B., Schweitzer J.B., et al. Expression of nerve growth factor receptors by Schwann cells of axotomized peripheral nerves: ultrastructural location, suppression by axonal contact, and binding properties. J Neurosci 1988, 8:664-681.
160. Tavakoli M., Malik R.A. Corneal confocal microscopy: a novel non-invasive technique to quantify small fibre pathology in peripheral neuropathies. J Vis Exp 2011, (47):2194. pii.
161. Tavakoli M., Kallinikos P., Iqbal A., et al. Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med 2011, 28:1261-1267.
162. Teitelman G., Guz Y., Ivkovic S., et al. Islet injury induces neurotrophin expression in pancreatic cells and reactive gliosis of peri-islet Schwann cells. J Neurobiol 1998, 34:304-318.
163. Teng H.K., Teng K.K., Lee R., et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 2005, 25:5455-5463.
164. Teng K.K., Felice S., Kim T., et al. Understanding proneurotrophin actions: recent advances and challenges. Dev Neurobiol 2010, 70:350-359.
165. Terenghi G., Mann D., Kopelman P.G., et al. trkA and trkC expression is increased in human diabetic skin. Neurosci Lett 1997, 228:33-36.
166. Thorleifsson G., Walters G.B., Gudbjartsson D.F., et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet 2009, 41:18-24.
167. Tomlinson D.R., Fernyhough P., Diemel L.T. Neurotrophins and peripheral neuropathy. Philos Trans R Soc Lond B Biol Sci 1996, 351:455-462.
168. Tonra J.R., Ono M., Liu X., et al. Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice. Diabetes 1999, 48:588-594.
169. Tsigos C., Diemel L.T., White A., et al. Cerebrospinal fluid levels of substance P and calcitonin-gene-related peptide: correlation with sural nerve levels and neuropathic signs in sensory diabetic polyneuropathy. Clin Sci 1993, 84:305-311.
170. Tsui H., Razavi R., Chan Y., et al. "Sensing" autoimmunity in type 1 diabetes. Trends Mol Med 2007, 13:405-413.
171. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
172. Unger T.J., Calderon G.A., Bradley L.C., et al. Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J Neurosci 2007, 27:14265-14274.
173. Valsecchi A.E., Franchi S., Panerai A.E., et al. The soy isoflavone genistein reverses oxidative and inflammatory state, neuropathic pain, neurotrophic and vasculature deficits in diabetes mouse model. Eur J Pharmacol 2011, 650:694-702.
174. Van Buren J.J., Bhat S., Rotello R., et al. Sensitization and translocation of TRPV1 by insulin and IGF-I. Mol Pain 2005, 1:17.
175. Verge V.M., Richardson P.M., Benoit R., et al. Histochemical characterization of sensory neurons with high-affinity receptors for nerve growth factor. J Neurocytol 1989, 18:583-591.
176. Verge V.M., Richardson P.M., Wiesenfeld-Hallin Z., et al. Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. J Neurosci 1995, 15:2081-2096.
177. Verge V.M., Gratto K.A., Karchewski L.A., et al. Neurotrophins and nerve injury in the adult. Philos Trans R Soc Lond B Biol Sci 1996, 351:423-430.
178. Verkhratsky A., Fernyhough P. Mitochondrial malfunction and Ca2+ dyshomeostasis drive neuronal pathology in diabetes. Cell Calcium 2008, 44:112-122.
179. Vidaltamayo R., Sanchez-Soto M.C., Hiriart M. Nerve growth factor increases sodium channel expression in pancreatic beta cells: implications for insulin secretion. FASEB J 2002, 16:891-892.
180. Vidaltamayo R., Mery C.M., Angeles-Angeles A., et al. Expression of nerve growth factor in human pancreatic beta cells. Growth Factors 2003, 21:103-107.
181. Vincent A.M., Hinder L.M., Pop-Busui R., et al. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Periph Nerv Syst 2009, 14:257-267.
182. von Bohlen und Halbach O., Minichiello L., Unsicker K. TrkB but not trkC receptors are necessary for postnatal maintenance of hippocampal spines. Neurobiol Aging 2008, 29:1247-1255.
183. Wang C., Bomberg E., Levine A., et al. Brain-derived neurotrophic factor in the ventromedial nucleus of the hypothalamus reduces energy intake. Am J Physiol Regul Integr Comp Physiol 2007, 293:R1037-R1045.
184. Wang Y.J., Valadares D., Sun Y., et al. Effects of proNGF on neuronal viability, neurite growth and amyloid-beta metabolism. Neurotox Res 2010, 17:257-267.
185. Wellmer A., Misra V.P., Sharief M.K., et al. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J Peripher Nerv Syst 2001, 6:204-210.
186. Wiedemann F.R., Siemen D., Mawrin C., et al. The neurotrophin receptor TrkB is colocalized to mitochondrial membranes. Int J Biochem Cell Biol 2006, 38:610-620.
187. Willer C.J., Speliotes E.K., Loos R.J., et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 2009, 41:25-34.
188. Wilson-Gerwing T.D., Dmyterko M.V., Zochodne D.W., et al. Neurotrophin-3 suppresses thermal hyperalgesia associated with neuropathic pain and attenuates transient receptor potential vanilloid receptor-1 expression in adult sensory neurons. J Neurosci 2005, 25:758-767.
189. Wilson-Gerwing T.D., Stucky C.L., McComb G.W., et al. Neurotrophin-3 significantly reduces sodium channel expression linked to neuropathic pain states. Exp Neurol 2008, 213:303-314.
190. Wilson-Gerwing T.D., Johnston J.M., Verge V.M. p75 neurotrophin receptor is implicated in the ability of neurotrophin-3 to negatively modulate activated ERK1/2 signaling in TrkA-expressing adult sensory neurons. J Comp Neurol 2009, 516:49-58.
191. Winston J.H., He Z.J., Shenoy M., et al. Molecular and behavioral changes in nociception in a novel rat model of chronic pancreatitis for the study of pain. Pain 2005, 117:214-222.
192. Woo N.H., Teng H.K., Siao C.J., et al. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 2005, 8:1069-1077.
193. Wu H., Lu D., Jiang H., et al. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma 2008, 25:130-139.
194. Wu Z., Mata M., Fink D.J. Prevention of diabetic neuropathy by regulatable expression of HSV-mediated erythropoietin. Mol Ther 2011, 19:310-317.
195. Xu B., Goulding E.H., Zang K., et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 2003, 6:736-742.
196. Xu W., Qiu C., Gatz M., et al. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 2009, 58:71-77.
197. Yamada M.K., Konishi Y., Kakinoki B., et al. Enhancement of Trk signaling pathways by the cholestane amide conjugate MCC-257. J Pharmacol Sci 2008, 108:131-134.
198. Yamanaka M., Itakura Y., Ono-Kishino M., et al. Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice. J Biosci Bioeng 2008, 105:395-402.
199. Yiangou Y., Facer P., Sinicropi D.V., et al. Molecular forms of NGF in human and rat neuropathic tissues: decreased NGF precursor-like immunoreactivity in human diabetic skin. J Peripher Nerv Syst 2002, 7:190-197.
200. Zhang Z., Winborn C.S., Marquez de Prado B., et al. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 2007, 27:2693-2703.
201. Zhu Y., Colak T., Shenoy M., et al. Nerve growth factor modulates TRPV1 expression and function and mediates pain in chronic pancreatitis. Gastroenterology 2011, 141:370-377.
202. Zochodne D.W. Diabetic polyneuropathy: an update. Curr Opin Neurol 2008, 21:527-533.
203. Zochodne D.W., Verge V.M., Cheng C., et al. Does diabetes target ganglion neurones? Progressive sensory neurone involvement in long-term experimental diabetes. Brain 2001, 124:2319-2334.